Inactive Instrument

Press Releases Merck & Co., Inc. Euronext Paris

Equities

MRK

US58933Y1055

Press Releases

Unlock all the news: Be the first to know and act before the market!

USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza	26/06	BU
Merck - U.S. FDA Approves CAPVAXIVE for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults	18/06	AQ
FDA Approves Merck s KEYTRUDA plus Carboplatin and Paclitaxel as Treatment for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma	18/06	AQ
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults	18/06	BU
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma	18/06	BU
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	05/06	BU
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	04/06	AQ
Anaveon announces IND approval of ANV600-001 Phase I/II clinical study	30/05	AQ
FDA Grants Priority Review to Merck's Application for KEYTRUDA plus Chemotherapy as First-Line Treatment of Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma	30/05	AQ
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival Endpoint in Patients with High-Risk Early-Stage Triple Negative Breast Cancer	29/05	AQ
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024	29/05	AQ
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma	29/05	BU
Merck to Acquire EyeBio	29/05	BU
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	29/05	AQ
Merck Announces Third-Quarter 2024 Dividend	29/05	BU
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)	28/05	BU
BioInvent Presents Promising Clinical Efficacy and Safety for anti-TNFR2 agent BI-1808 at ASCO 2024	24/05	AQ
BioInvent Presents Promising Phase 1 Data for BI-1206 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors at ASCO 2024	24/05	AQ
MSD collaboration to drive development of solid tumour combination therapy	21/05	AQ
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation	21/05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Merck & Co., Inc. Euronext Paris

Equities

MRK

US58933Y1055

Press Releases

Filters